BHF177 Suppresses Diabetic Neuropathic Pain by Blocking PKC/CaMKII/ERK1/2/CREB Signaling Pathway through Activating GABA_B Receptor.

ABSTRACT: The gamma-aminobutyric acid type B (GABA_B) receptor may participate in the development of diabetic neuropathic pain (DNP). BHF177 serves as a positive allosteric modulator of the GABA_B receptor. In the current study, we sought to study the role of the BHF177-GABA_B receptor in DNP and its underlying mechanism. Streptozotocin was adopted to induce a rat model of DNP, followed by determination of the paw withdrawal threshold (PWT), paw withdrawal latency (PWL), and glucose level. The effect of BHF177 on DNP by regulating the GABA_B receptor in vivo was determined by the injection of BHF177 and/or CGP46381 (a GABA_B receptor antagonist) into rat models of DNP. Hippocampal neuronal cells were isolated and cultured, and the neurons and DNP mod

SUBMITTER: Liu B 

PROVIDER: S-EPMC9691330 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature